Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The company has been sold to Shinshin Pharmaceuticals
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Subscribe To Our Newsletter & Stay Updated
